浙江海正药业股份有限公司 关于全资子公司浙江省医药工业有限公司100%股权转让公开挂牌的公告

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has approved the public transfer of 100% equity of its wholly-owned subsidiary, Zhejiang Pharmaceutical Industry Co., Ltd., to optimize its business structure and focus on core advantages in the pharmaceutical industry [1][2] Group 1 - The board of directors has confirmed that the announcement contains no false records, misleading statements, or significant omissions, and they bear legal responsibility for its authenticity, accuracy, and completeness [1] - The equity of Zhejiang Pharmaceutical Industry Co., Ltd. is assessed at 392.2339 million yuan, with a proposed public listing price of 430 million yuan [1] - The public transfer application for the equity was submitted to Taizhou Property Rights Exchange on November 10, 2025, with the listing period from November 11 to December 8, 2025 [2] Group 2 - The company has provided details for the public transfer on the websites of Zhejiang Property Rights Exchange and Taizhou Property Rights Exchange, and investors can inquire further by phone [2] - There is a potential risk of unsuccessful delisting for the public transfer of the equity, and the company will fulfill its information disclosure obligations based on the progress of this matter [2] - The designated media for information disclosure includes China Securities Journal, Shanghai Securities Journal, Securities Times, and the Shanghai Stock Exchange website [2]